Project 1 is concerned with assessment and prediction of exposure of human and ecological receptors to contaminants in the environment. Our goals are to;i) determine how environmental fate and transport processes that act upon contaminants control the level and duration of potential exposure and, ii) develop useful methods and approaches to estimate exposure concentrations and, in collaboration with other Superfund projects, biological effects. Specific objectives include providing fundamental knowledge about the processes controlling the transport and transformation of contaminants, especially those related to complex mixtures;developing molecular-based and biosensor technologies and integrated tools for monitoring bioremediation and natural attenuation;and developing new models of reactive transport in groundwater and applying them to predict chemical exposure risks and remediation. We will consider three complex mixtures and their constituents as examples of Superfund-relevant and emerging issues related to fate, transport and transformation of contaminants in the environment. These include;i) biosolids from waste water treatment that contain pharmaceuticals, personal care and household products such as TCC/TCS and PBDEs, nanoparticles, and other chemicals of concern;ii) biofuels and fuel additives that include oxygenates;and iii) formulated pesticides such as pyrethroids. This grouping of compounds allows us to examine in a unique and integrated way the roles of particle size, surface characteristics, and co-occurring substances on contaminant fate and transport. Based on our research we will develop general principles and approaches that will be applicable to broader groups of contaminants not considered here and help predict emergence of new environmental contaminants.

Public Health Relevance

This project is relevant to public health because it will result in development of tools for assessment or prediction of the exposure of human populations to current and emerging contaminants of concern to the Superfund mission.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
5P42ES004699-25
Application #
8252230
Study Section
Special Emphasis Panel (ZES1)
Project Start
Project End
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
25
Fiscal Year
2011
Total Cost
$233,001
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications